X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (895) 895
Publication (60) 60
Patent (15) 15
Conference Proceeding (3) 3
Book Review (2) 2
Web Resource (2) 2
Book Chapter (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (384) 384
male (226) 226
index medicus (218) 218
female (217) 217
middle aged (208) 208
hematology (206) 206
adult (194) 194
oncology (142) 142
aged (136) 136
transplantation (105) 105
adolescent (95) 95
cancer (72) 72
treatment outcome (70) 70
leukemia (69) 69
stem cells (67) 67
immunology (61) 61
young adult (61) 61
transplantation, homologous (60) 60
chemotherapy (55) 55
prognosis (54) 54
hematology, oncology and palliative medicine (52) 52
acute myeloid leukemia (48) 48
hematopoietic stem cells (48) 48
hematopoietic stem cell transplantation (46) 46
acute myeloid-leukemia (45) 45
analysis (45) 45
survival analysis (44) 44
therapy (44) 44
aged, 80 and over (42) 42
leukemia, myeloid, acute - genetics (42) 42
retrospective studies (42) 42
leukemia, myeloid, acute - mortality (41) 41
research (41) 41
acute myelogenous leukemia (36) 36
aml (36) 36
bone-marrow-transplantation (36) 36
recurrence (36) 36
leukemia, myeloid, acute - therapy (35) 35
animals (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
disease-free survival (34) 34
mutation (33) 33
stem-cell transplantation (33) 33
acute disease (32) 32
leukemia, myeloid, acute - drug therapy (32) 32
bone marrow (31) 31
expression (31) 31
survival (31) 31
care and treatment (30) 30
abridged index medicus (28) 28
bone-marrow (28) 28
hematopoietic stem cell transplantation - methods (28) 28
risk factors (28) 28
child (27) 27
prospective studies (27) 27
remission induction (27) 27
versus-host-disease (27) 27
stem cell transplantation (26) 26
t cells (26) 26
antineoplastic agents - therapeutic use (25) 25
cell biology (24) 24
germany (24) 24
mortality (24) 24
hematopoietic stem cell transplantation - adverse effects (23) 23
mice (23) 23
myelodysplastic syndrome (23) 23
patients (23) 23
bone-marrow transplantation (22) 22
immunotherapy (22) 22
risk (22) 22
flow cytometry (21) 21
mutations (21) 21
progenitor cells (21) 21
article (20) 20
fms-like tyrosine kinase 3 - genetics (20) 20
leukemia, myeloid, acute - pathology (20) 20
medicine (20) 20
medicine & public health (20) 20
pharmacokinetics (20) 20
relapse (20) 20
survival rate (20) 20
transplantation conditioning - methods (20) 20
follow-up studies (19) 19
gene expression (19) 19
tissue donors (19) 19
unrelated donors (19) 19
cells, cultured (18) 18
health aspects (18) 18
medicine, research & experimental (18) 18
transplants & implants (18) 18
adults (17) 17
cohort studies (17) 17
infection (17) 17
multidisciplinary sciences (17) 17
myelodysplastic syndromes (17) 17
research article (17) 17
allogeneic stem cell transplantation (16) 16
colony-stimulating factor (16) 16
cytogenetics (16) 16
further section (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 08/2013, Volume 123, Issue 8, pp. 3272 - 3291
Journal Article
Journal Article
Blood, ISSN 0006-4971, 05/2015, Volume 125, Issue 21, pp. 3246 - 3252
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2014, Volume 9, Issue 4, p. e95517
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9850, pp. 1309 - 1316
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article